PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 211/58, A61K 31/435, 31/41, C07D 207/14, 211/56, 211/26, 207/09, 401/12, 405/12, 409/12, 413/06, 413/14, 409/06, 405/06

A1

(11) International Publication Number: WO 99/25686

(43) International Publication Date: 27 May 1999 (27.05.99)

(21) International Application Number: PCT/US98/23254

(22) International Filing Date: 17 November 1998 (17.11.98)

(30) Priority Data:

08/972,484	18 November 1997 (18.11.97)	US
09/055,285	6 April 1998 (06.04.98)	US
09/133,434	13 August 1998 (13.08.98)	US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications

US	08/972,484 (CIP)
Filed on	18 November 1997 (18.11.97)
US	09/055,285 (CIP)
Filed on	6 April 1998 (06.04.98)
US	09/133,434 (CIP)
Filed on	13 August 1998 (13.08.98)

(71) Applicants *(for all designated States except US)*: TEIJIN LIMITED [JP/JP]; 6–7, Minamihommachi 1–chome, Chuo–ku, Osaka–shi, Osaka 541–0054 (JP). COMBICHEM, INC. [US/US]; 9050 Camino Santa Fe, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: SHIOTA, Tatsuki [JP/JP]; Teijin Limited, Tokyo Research Center, 4–3–2, Asahigaoka, Hino–shi, Tokyo 191 (JP). KATAOKA, Ken–ichiro [JP/JP]; Teijin Limited, Tokyo Research Center, 4–3–2, Asahigaoka, Hino–shi, Tokyo 191 (JP). IMAI, Minoru [JP/JP]; Teijin Limited, Tokyo Research Center, 4–3–2, Asahigaoka, Hino–shi, Tokyo 191 (JP). TSUTSUMI, Takaharu [JP/JP]; Teijin Limited, Tokyo Research Center, 4–3–2, Asahigaoka, Hino–shi, Tokyo 191 (JP). SUDOH, Masaki [JP/JP]; Teijin Limited, Tokyo Research Center, 4–3–2, Asahigaoka, Hino–shi, Tokyo 191 (JP). SOGAWA, Ryo [JP/JP]; Teijin Limited, Tokyo Research Center, 4–3–2, Asahigaoka, Hino–shi, Tokyo 191 (JP). MORITA, Takuya [JP/JP]; Teijin Limited, Tokyo Research Center, 4–3–2, Asahigaoka, Hino–shi, Tokyo 191 (JP). HADA, Takahiko [JP/JP]; Teijin Limited, Tokyo Research Center, 4–3–2, Asahigaoka, Hino–shi, Tokyo 191 (JP). MUROGA, Yumiko [JP/JP]; Teijin Limited, Tokyo Research Center, 4–3–2, Asahigaoka, Hino–shi, Tokyo 191 (JP). TAKENOUCHI, Osami [JP/JP]; Teijin Limited, Tokyo Research Center, 4–3–2, Asahigaoka, Hino–shi, Tokyo 191 (JP). FURUYA, Monoru [JP/JP]; Teijin Limited, Tokyo Research Center, 4–3–2, Asahigaoka, Hino–shi, Tokyo 191 (JP). ENDO, Noriaki [JP/JP]; Teijin Limited, Tokyo Research Center, 4–3–2, Asahigaoka, Hino–shi, Tokyo 191 (JP). TARBY, Christine, M. [US/US]; CombiChem, Inc., 9050 Camino Santa Fe, San Diego, CA 92121 (US). MOREE, Wilna [NL/US]; CombiChem, Inc., 9050 Camino Santa Fe, San Diego, CA 92121 (US). TEIG, Steven, L. [US/US]; CombiChem North, Suite 201, 1804 Embarcadero Road, Palo Alto, CA 94303 (US).

(74) Agents: BIGGART, Waddell, A. et al.; Sughrue, Mion, Zinn, MacPeak & Seas, PLLC, Suite 800, 2100 Pennsylvania Avenue, N.W., Washington, DC 20037–3202 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
With amended claims.

Date of publication of the amended claims:
8 July 1999 (08.07.99)

(54) Title: CYCLIC AMINE DERIVATIVES AND THEIR USE AS DRUGS



(I)

(57) Abstract

A compound represented by general formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C_1–C_6 alkyl addition salt thereof, and their medical applications. Since these compounds inhibit the action of chemokines such as MIP–1α and/or MCP–1 on target cells, they may be useful as a therapeutic drug and/or preventative drug in diseases, such as atherosclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissues.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

[received by the International Bureau on 19 May 1999 (19.05.99);
original claim 1 amended; remaining claims unchanged (2 pages)]

ring, and the phenyl group, C_3-C_8 cycloalkyl group, C_3-C_8 cycloalkenyl group, benzyl group, aromatic heterocyclic group, or condensed ring may be substituted with one or more of a halogen atom, a hydroxy group, a mercapto group, a cyano group, a nitro group, a thiocyanato group, a carboxy group, a carbamoyl group, a trifluoromethyl group, a C_1-C_6 alkyl group, a C_3-C_6 cycloalkyl group, a C_2-C_6 alkenyl group, a C_1-C_6 alkoxy group, a C_3-C_8 cycloalkyloxy group, a C_1-C_6 alkylthio group, a C_1-C_3 alkylenedioxy group, a phenyl group, a phenoxy group, a phenylamino group, a benzyl group, a benzoyl group, a phenylsulfinyl group, a phenylsufonyl group, a 3-phenylureido group, a C_2-C_7 alkanoyl group, a C_2-C_7 alkoxycarbonyl group, a C_2-C_7 alkanoyloxy group, a C_2-C_7 alkanoylamino group, a C_2-C_7 N-alkylcarbamoyl group, a C_1-C_6 alkylsulfonyl group, a phenylcarbamoyl group, a N,N-di (C_1-C_6 alkyl) sulfamoyl group, an amino group, a mono (C_1-C_6 alkyl) amino group, a di (C_1-C_6 alkyl) amino group, a benzylamino group, a C_2-C_7 (alkoxycarbonyl) amino group, a C_1-C_6 (alkylsulfonyl) amino group, or a bis (C_1-C_6 alkylsulfonyl) amino group, wherein the substituent for the phenyl group, C_3-C_8 cycloalkyl group, C_3-C_8 cycloalkenyl group, benzyl group, aromatic heterocyclic group, or condensed ring is optionally substituted with one or more of a halogen atom, a cyano group, a hydroxy group, an amino group, a trifluoromethyl group, a C_1-C_6 alkyl group, a C_1-C_6 alkoxy group, a C_1-C_6 alkylthio group, a mono (C_1-C_6 alkyl) amino group, or a di (C_1-C_6 alkyl) amino group, with the proviso that when $k = 2$, $m = 2$, $n = 0$, and the phenyl group in R^1 is not substituted, C_1-C_6 alkyl group as a substituent for the phenyl group, C_3-C_8 cycloalkyl group, C_3-C_8 cycloalkenyl group, benzyl group, aromatic heterocyclic group, or condensed ring in R^6 is not substituted with an amino group and R^6 is not a benzyl group.

2. A compound, its pharmaceutically acceptable acid addition salt or its pharmaceutically acceptable C_1-C_6 alkyl addition salt as set forth in claim 1, wherein $k = 1$ and $m = 2$ in the above formula (I).

3. A compound, its pharmaceutically acceptable acid addition salt or its pharmaceutically acceptable C_1-C_6 alkyl addition salt as set forth in claim 2, wherein $n = 0$ in the above formula (I).

4. A compound, its pharmaceutically acceptable acid addition salt or its pharmaceutically acceptable C_1-C_6 alkyl addition salt as set forth in claim 1, wherein k = 0, m = 3 and n = 1 in the above formula (I).

5. A compound, its pharmaceutically acceptable acid addition salt or its pharmaceutically acceptable C_1-C_6 alkyl addition salt as set forth in claim 1, wherein k = 1 and m = 3 in the above formula (I).